Jonathan W.  Ayers net worth and biography

Jonathan Ayers Biography and Net Worth

Director of IDEXX Laboratories
Mr. Ayers has served as Senior Advisor to the Company since November 2019. Prior to that, Mr. Ayers served as the Chair of the Board from January 2002 to November 2019 and served as President and Chief Executive Officer of IDEXX from January 2002 to June 2019. Before joining IDEXX, Mr. Ayers held various executive leadership positions at United Technologies Corporation and its business unit Carrier Corporation from 1995 - 2001. Prior to that, Mr. Ayers held various investment banking positions at Morgan Stanley & Co. for nine years. Mr. Ayers holds an undergraduate degree in molecular biophysics and biochemistry from Yale University and an MBA from Harvard Business School, with high distinction.

What is Jonathan W. Ayers' net worth?

The estimated net worth of Jonathan W. Ayers is at least $56.94 million as of May 18th, 2023. Mr. Ayers owns 137,039 shares of IDEXX Laboratories stock worth more than $56,943,816 as of January 5th. This net worth evaluation does not reflect any other investments that Mr. Ayers may own. Learn More about Jonathan W. Ayers' net worth.

How do I contact Jonathan W. Ayers?

The corporate mailing address for Mr. Ayers and other IDEXX Laboratories executives is ONE IDEXX DRIVE, WESTBROOK ME, 04092. IDEXX Laboratories can also be reached via phone at (207) 556-0300 and via email at investorrelations@idexx.com. Learn More on Jonathan W. Ayers' contact information.

Has Jonathan W. Ayers been buying or selling shares of IDEXX Laboratories?

Jonathan W. Ayers has not been actively trading shares of IDEXX Laboratories in the last ninety days. Most recently, Jonathan W. Ayers sold 10,000 shares of the business's stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $489.23, for a transaction totalling $4,892,300.00. Following the completion of the sale, the director now directly owns 137,039 shares of the company's stock, valued at $67,043,589.97. Learn More on Jonathan W. Ayers' trading history.

Who are IDEXX Laboratories' active insiders?

IDEXX Laboratories' insider roster includes Jonathan Ayers (Director), Bruce Claflin (Director), George Fennell (SVP), Rebecca Henderson (Director), Nimrata Hunt (EVP), Daniel Junius (Director), Michael Lane (EVP), Jonathan Mazelsky (CEO), Brian Mckeon (CFO), James Polewaczyk (EVP), M. Szostak (Director), Kathy Turner (SVP), Kathy Turner (SVP), Giovani Twigge (SVP), and Sophie Vandebroek (Director). Learn More on IDEXX Laboratories' active insiders.

Are insiders buying or selling shares of IDEXX Laboratories?

During the last year, insiders at the sold shares 5 times. They sold a total of 44,068 shares worth more than $25,124,750.88. The most recent insider tranaction occured on November, 27th when Director Sophie V Vandebroek sold 344 shares worth more than $144,631.36. Insiders at IDEXX Laboratories own 2.1% of the company. Learn More about insider trades at IDEXX Laboratories.

Information on this page was last updated on 11/27/2024.

Jonathan W. Ayers Insider Trading History at IDEXX Laboratories

Jonathan W. Ayers Buying and Selling Activity at IDEXX Laboratories

This chart shows Jonathan W Ayers's buying and selling at IDEXX Laboratories by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

IDEXX Laboratories Company Overview

IDEXX Laboratories logo
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Read More

Today's Range

Now: $415.53
Low: $407.09
High: $417.30

50 Day Range

MA: $424.43
Low: $406.92
High: $451.08

2 Week Range

Now: $415.53
Low: $398.50
High: $583.39

Volume

341,211 shs

Average Volume

357,505 shs

Market Capitalization

$34.03 billion

P/E Ratio

40.07

Dividend Yield

N/A

Beta

1.36